menu
    • menu

    Company profile for Intellia Therapeutics

    NEW Drugs in Dev: 11
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Many of us pursuing work in the biotechnology industry are inspired by someone in our community who is living with a disease or the loss of a loved one. We know that rare and genetic diseases not only affect the people living with often debilitating and life-threatening symptoms, but that these disorders also significantly impact their families, friends and caregivers. Since the emergence of the breakthrough genome editing ...
    Many of us pursuing work in the biotechnology industry are inspired by someone in our community who is living with a disease or the loss of a loved one. We know that rare and genetic diseases not only affect the people living with often debilitating and life-threatening symptoms, but that these disorders also significantly impact their families, friends and caregivers. Since the emergence of the breakthrough genome editing technology CRISPR/Cas9, the science has moved fast in only a few years.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Intellia TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    40 Erie Street, Cambridge, MA 02139
    Telephone
    Telephone
    857-285-6200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.intelliatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS Asia

    IMCAS Asia

    Not Confirmed

    envelop Contact Supplier

    IMCAS Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Intellia Reports Positive Phase 3 Data for HAE Gene Therapy
    Intellia Reports Positive Phase 3 Data for HAE Gene Therapy

    13 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/13/3311378/0/en/intellia-therapeutics-reports-additional-positive-phase-3-results-for-lonvoguran-ziclumeran-lonvo-z-in-patients-with-hereditary-angioedema.html

    GLOBENEWSWIRE
    13 Jun 2026
    Share Share
    Intellia Therapeutics Reports Inducement Grants on Nasdaq
    Intellia Therapeutics Reports Inducement Grants on Nasdaq

    05 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/05/3307600/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Jun 2026
    Share Share
    Intellia to Report Additional Phase 3 HAELO Data
    Intellia to Report Additional Phase 3 HAELO Data

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304241/0/en/intellia-therapeutics-to-report-additional-phase-3-haelo-data-for-lonvoguran-ziclumeran-lonvo-z-in-late-breaking-oral-presentation-at-eaaci-2026.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Intellia Therapeutics Announces Q1 2026 Financial Results
    Intellia Therapeutics Announces Q1 2026 Financial Results

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3291773/0/en/intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share
    Intellia Therapeutics to Present at Investor Conferences
    Intellia Therapeutics to Present at Investor Conferences

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3287537/0/en/intellia-therapeutics-to-participate-in-upcoming-investor-conferences.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Gene Therapy's Evidence Problem—Lessons From Recent FDA Decisions
    Gene Therapy's Evidence Problem—Lessons From Recent FDA Decisions

    04 May 2026

    // BIOSPACE

    https://www.biospace.com/fda/opinion-gene-therapys-evidence-problem-lessons-from-recent-fda-decisions

    BIOSPACE
    04 May 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search